BofA raised the firm’s price target on Ascendis Pharma (ASND) to $216 from $201 and keeps a Buy rating on the shares. The firm notes the company ...

Eli Lilly is partnering with Camurus, a company with technology that extends how long an injectable drug lasts in the body, ...

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for TransCon ® CNP (navepegritide) for the treatment of children with achondroplasia, a rare ...

Ascendis Pharma A/S (NASDAQ:ASND ... strategy to become a global leader in the treatment of growth disorder. TransCon CNP, the first long acting therapy in development for the treatment of ...

Ascendis Pharma's President and Chief Executive Officer. "We look forward to potential approvals of our third product, TransCon CNP, as a monotherapy in children with achondroplasia, and we believe ...

Ascendis Pharma’s President and Chief Executive Officer. “We look forward to potential approvals of our third product, TransCon CNP, as a monotherapy in children with achondroplasia ...

Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has submitted its New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for TransCon CNP (navepegritide) for the ...

COPENHAGEN, Denmark, March 31, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has submitted its New Drug Application (NDA) to the U.S. Food & Drug Administration ...

The adjustment follows the announcement of positive topline results from Ascendis Pharma's Phase 3 ApproaCH study of TransCon CNP in achondroplasia, a bone growth disorder. The study successfully ...

Also Read: Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In. In the trial, children treated with once-weekly TransCon CNP demonstrated annualized growth ...